On July 17, 2026, San Carlos based Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) revealed the approval of granting inducement stock options on July 16, 2026. The options cover a total of 139,930 shares of the company's common stock and have been offered to seventeen fresh, non-executive employees. Iovance focuses on developing innovative polyclonal tumor infiltrating lymphocyte ("TIL") therapies for cancer patients.